Investing.comQwen · 实盘不做把握 9/10不做原因:无可交易标的
北京时间·🕒 发布 18:48:41·⟳ 抓取 18:49:19 +38s·⚡ 决策 08-31 20:33:53 +1h44m·56.8 天前
礼来以最高28.75亿美元现金收购自身免疫疾病生物技术公司Merida Biosciences
Merida为私有公司无可交易证券；收购方礼来市值约$800-900B，$2.875B收购仅占市值约0.3%，属超大市值公司的微型管线补充，不构成短线可交易催化。无A股/港股供应链或竞争映射关系。
📄 原文Investing.com↗ 原文
Lilly to acquire Merida Biosciences for up to $2.875 billion
Oil rises 3% as U.S. strikes on Iran revive Hormuz supply disruption concerns INDIANAPOLIS and CAMBRIDGE, Mass. - Eli L…
不做 Eli Lilly（礼来）（LLY.US）
超大市值（~$850B）公司收购$2.875B私有biotech，仅占市值约0.3%，属管线bolt-on补充，不构成短线价格催化。Merida为私有公司无可交易证券。无A股/港股因果映射。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
礼来（市值~$850B）以最高$2.875B收购私有biotech Merida（lead asset MER511 Phase 1，Graves' disease自身抗体降解机制）。收购金额仅占礼来市值约0.3%，属典型管线bolt-on，对礼来股价无实质短线影响。Merida为私有公司无可交易证券。该收购涉及全新机制（选择性降解致病性自身抗体），与A股/港股公司无供应链、竞争或客户层面的因果映射。结论：无可交易机会。
🔎 新鲜度:最早出现 2026-08-31 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无需先例校准——事件因标的不可交易/市值占比过小直接AVOID，不进入先例定价环节
工具执行结果 · 成功 1 · 降级 2 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 5,600 ms
{"result": "search_processed_events:agent query=`eli lilly acquire merida biosciences | lly merida $2.875 billion autoimmune | merida biosciences mer511 graves disease`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.3/72 小时、1065 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - stock_quote 降级 stock_tools HTTP · 9,226 ms
取价失败: Futu returned no quote - stock_quote 降级 stock_tools HTTP · 7,879 ms
取价失败: Futu returned no quote
原文全文
展开原文 · 2,248 字
Oil rises 3% as U.S. strikes on Iran revive Hormuz supply disruption concerns
INDIANAPOLIS and CAMBRIDGE, Mass. - Eli Lilly and Company (NYSE:LLY) announced today a definitive agreement to acquire Merida Biosciences, Inc., a biotechnology company developing therapeutics for autoimmune and allergic diseases, for up to $2.875 billion in cash.
The acquisition includes an upfront payment and contingent milestone payments, according to a press release statement. The transaction is subject to customary closing conditions and regulatory approvals, with an expected close in the fourth quarter of 2026.
Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies. The company’s lead program, MER511, is in Phase 1 development for Graves’ disease and thyroid eye disease. Initial Phase 1 data showed MER511 achieved reductions in pathogenic thyroid-stimulating antibodies.
Graves’ disease affects approximately 3 million people in the U.S., and roughly 25 to 40 percent of people with Graves’ disease develop thyroid eye disease. Current approved treatments for both conditions do not directly target the autoantibodies that cause them.
Merida’s pipeline also includes MER769, a preclinical program focused on food allergy, asthma, chronic spontaneous urticaria and other diseases, along with earlier-stage programs in kidney diseases such as membranous nephropathy.
"We’re building our pipeline around therapies that meaningfully change the course of disease, not just its downstream effects," said Francisco Ramírez-Valle, senior vice president of Lilly immunology research and early clinical development.
Adam Townsend, chief executive officer of Merida, said the acquisition "gives our science the resources and commitment to realize its potential for patients with immune-mediated conditions."
Lilly will determine the accounting treatment of this transaction in accordance with Generally Accepted Accounting Principles upon closing.
Centerview Partners LLC is acting as financial advisor to Merida, with Goodwin Procter LLP serving as legal counsel. Ropes & Gray LLP is acting as legal counsel to Lilly.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
INDIANAPOLIS and CAMBRIDGE, Mass. - Eli Lilly and Company (NYSE:LLY) announced today a definitive agreement to acquire Merida Biosciences, Inc., a biotechnology company developing therapeutics for autoimmune and allergic diseases, for up to $2.875 billion in cash.
The acquisition includes an upfront payment and contingent milestone payments, according to a press release statement. The transaction is subject to customary closing conditions and regulatory approvals, with an expected close in the fourth quarter of 2026.
Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies. The company’s lead program, MER511, is in Phase 1 development for Graves’ disease and thyroid eye disease. Initial Phase 1 data showed MER511 achieved reductions in pathogenic thyroid-stimulating antibodies.
Graves’ disease affects approximately 3 million people in the U.S., and roughly 25 to 40 percent of people with Graves’ disease develop thyroid eye disease. Current approved treatments for both conditions do not directly target the autoantibodies that cause them.
Merida’s pipeline also includes MER769, a preclinical program focused on food allergy, asthma, chronic spontaneous urticaria and other diseases, along with earlier-stage programs in kidney diseases such as membranous nephropathy.
"We’re building our pipeline around therapies that meaningfully change the course of disease, not just its downstream effects," said Francisco Ramírez-Valle, senior vice president of Lilly immunology research and early clinical development.
Adam Townsend, chief executive officer of Merida, said the acquisition "gives our science the resources and commitment to realize its potential for patients with immune-mediated conditions."
Lilly will determine the accounting treatment of this transaction in accordance with Generally Accepted Accounting Principles upon closing.
Centerview Partners LLC is acting as financial advisor to Merida, with Goodwin Procter LLP serving as legal counsel. Ropes & Gray LLP is acting as legal counsel to Lilly.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。